In 2018, McGough completed a $40M rework of piping, electrical and ancillary structural and architectural changes for the production of two different commercial monoclonal antibody products utilizing the large scale and small-scale trains. Engineered by CRB, the project primarily involved major changes to hygenic and utility piping and instrumentation, equipment, rooms and platforms. As part of the project services, McGough also procured selected process equipment.
